Health Library
April 24, 2026
Question on this topic? Get an instant answer from August.
Two oral GLP-1 drugs are FDA approved for weight loss right now. Wegovy pill (oral semaglutide 25 mg) and Foundayo (orforglipron). Both are daily pills. Both produce double digit weight loss.
If you've wanted to try a GLP-1 for weight loss but didn't want injections, you now have options that work.
Wegovy pill is stronger one. In the OASIS 4 trial, people on oral semaglutide 25 mg lost 13.6% of their body weight at 64 weeks. Those who stayed on full course lost 16.6%.
For someone starting at 230 pounds, that's roughly 31 to 38 pounds.
Foundayo (orforglipron) produced about 12.4% weight loss at highest dose over 72 weeks in ATTAIN-1 trial. That's about 28 pounds for same starting weight.
Both numbers are in range that matters medically. A 10% or greater weight loss can lower blood pressure, improve blood sugar, reduce joint pain, and cut cardiovascular risk.

Wegovy pill produces roughly same weight loss as injectable Wegovy (semaglutide 2.4 mg). The STEP 1 trial showed 14.9% with injection. The OASIS 4 trial showed 13.6% to 16.6% with pill. Those ranges overlap.
Foundayo produces less weight loss than injectable tirzepatide (Zepbound), which can reach 20% to 22%. But it produces more than liraglutide (Saxenda), which tops out around 5% to 8%.
Short version: the pills are competitive with injections but don't quite match tirzepatide.
Same criteria as injectables. BMI of 30 or higher. Or BMI of 27 or higher with at least one weight-related condition like high blood pressure, high cholesterol, prediabetes, or sleep apnea.
You don't need to have diabetes. Both Wegovy pill and Foundayo are approved for people without diabetes. The OASIS 4 trial specifically excluded people with diabetes.
If you're unsure about eligibility, our article on how to get Mounjaro without diabetes covers how weight-loss prescriptions work for non-diabetic patients. The same principles apply to oral drugs.
The two pills have different rules.
Wegovy pill: Take it first thing in the morning on an empty stomach. Use no more than 4 ounces of plain water. Wait 30 minutes before eating, drinking anything else, or taking other medications. This timing is strict because drug needs an empty stomach to absorb properly.
Foundayo: Take it any time of day. With or without food. No water restrictions. This flexibility is its biggest practical advantage.
Both drugs start at a low dose and increase monthly. Wegovy pill goes from 1.5 mg up to 25 mg over about four months. Foundayo goes from 0.8 mg up to 17.2 mg.
The same ones as injectable GLP-1 drugs. Nausea, diarrhea, vomiting, and constipation are most common. They're worst during dose escalation and usually improve after first couple of months.
Oral semaglutide can also cause more stomach discomfort than injectable version. The drug is absorbed through stomach lining, so it acts locally on GI tract during absorption.
Sulfur burps happen with oral semaglutide too, not just injectables. Eating smaller meals and avoiding high-sulfur foods can help.
Foundayo's side effect profile is similar. Nausea and diarrhea are most reported. Rates in ATTAIN trials were comparable to what you'd see with injectable GLP-1 drugs.
Both start at $149 per month for lowest dose for self-pay patients.
Wegovy pill offers starting dose (1.5 mg) and 4 mg dose at $149/month through NovoCare. Higher doses cost more. With commercial insurance and a savings card, copays can drop to $0 to $25.
Foundayo offers similar pricing. Eli Lilly's savings card can bring cost to $25/month for commercially insured patients. Medicare Part D patients may pay $50/month starting July 2026.
Without any savings programs or insurance, GLP-1 pills cost less to manufacture than injectables. That pricing advantage may grow as production scales up.
Yes. If you're on injectable Wegovy and want to try pill version, the switch is straightforward since it's same molecule. Your doctor will match your oral dose to your injectable dose based on clinical equivalence.
If you're switching from tirzepatide (Zepbound or Mounjaro) to an oral GLP-1, transition takes more thought. Tirzepatide works on two receptors while oral semaglutide works on one. You may experience some return of appetite during switch. Your doctor can help plan timing.
Switching from an injectable to Foundayo is also possible. Since it's a different molecule, your doctor will likely start at a mid-range dose rather than bottom.
Rybelsus (oral semaglutide 7 mg and 14 mg) is not approved for weight loss. It's approved for type 2 diabetes. The doses are lower than Wegovy pill. Weight loss is modest, around 3% to 5%.
Some doctors prescribe it off-label for weight management. But if weight loss is your primary goal, Wegovy pill or Foundayo will produce better results.
Pick based on what matters most to you.
If you want most weight loss from a pill, Wegovy pill has stronger data. If 30 minute morning fasting rule doesn't bother you, it's top choice.
If you want simplicity, Foundayo is easier to work into any routine. Slightly less weight loss, but no timing restrictions at all.
Your doctor can factor in your insurance, your health history, and your daily schedule to help you decide.
Get clear medical guidance
on symptoms, medications, and lab reports.
Download August today. No appointments. Just answers you can trust.